Pelvic exenteration (PE) is one of the most radical surgical approaches. In earlier times, PE was associated with high morbidity and mortality. Nowadays, due to improved selection of suitable patients, perioperative settings, and postoperative care, patients’ outcomes have been optimized. To investigate patients’ outcomes and identify possible influencing clinical and histopathological factors, we analysed 17 patients with recurrent vulvar cancer who underwent PE in our department between 2007 and 2022. The median age was 64.9 years, with a difference of 40 years between the youngest and the oldest patient (41 vs. 81 years). The mean overall survival time was 55.7 months; the longest survival time reached up to 164 months. The achievement of complete cytoreduction (p= 0.02), the indication for surgery (curative vs. palliative), and the presence of distant metastases (bothp= 0.01) showed a significant impact on overall survival. The presence of lymphatic metastases (p= 0.11) seems to have an influence on overall survival (OS) time. Major complications appeared in 35% of the patients. Our results support the existing data for PE in cases of recurrent vulvar cancer; for a group of selected patients, PE is a treatment option with good overall survival times and acceptable morbidity.
盆腔廓清术是最为激进的手术方式之一。早期该手术伴随较高的并发症发生率和死亡率。如今，通过改进患者筛选标准、优化围手术期管理及术后护理，患者预后已得到显著改善。为探究患者预后情况并识别可能影响的临床及组织病理学因素，我们分析了2007年至2022年间在本科室接受盆腔廓清术的17例外阴癌复发患者资料。患者中位年龄为64.9岁，最年轻与最年长患者年龄差达40岁（41岁 vs 81岁）。平均总生存期为55.7个月，最长生存期达164个月。完全肿瘤细胞减灭术的达成（p=0.02）、手术指征（根治性 vs 姑息性）以及远处转移的存在（两者p=0.01）对总生存期具有显著影响。淋巴转移的存在（p=0.11）似乎也对总生存期产生影响。35%的患者出现主要并发症。本研究结果支持现有关于外阴癌复发患者行盆腔廓清术的数据：对于经过筛选的患者群体，盆腔廓清术是一种能够获得良好总生存期且并发症发生率可接受的治疗选择。
Pelvic Exenteration for Recurrent Vulvar Cancer: A Retrospective Study
肿瘤(癌症)患者之家